Pharma major Lupin on Friday said it has received approval from the US health regulator for its generic Levothyroxine Sodium tablets used for treatment of hypothyroidism and pituitary thyrotropin suppression.
The company has received approval from the United States Food and Drug Administration (USFDA) to market its Levothyroxine Sodium tablets USP in the strengths of 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg, Lupin said in a statement.
The product is a generic version of Jerome Stevens Pharmaceuticals Inc's Unithroid tablets in the same strengths, it added.
According to IQVIA MAT June 2019 data, Levothyroxine Sodium tablets USP had total annual sales of about USD 2,581 million in the US, Lupin said.
The tablets are indicated for hypothyroidism and pituitary thyrotropin suppression, it added.
Shares of Lupin Ltd closed at Rs 756 per scrip on the BSE, up 1.98 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app